KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Aurinia Pharmaceuticals (AUPH) EPS (Basic) (2018 - 2025)

Historic EPS (Basic) for Aurinia Pharmaceuticals (AUPH) over the last 10 years, with Q3 2025 value amounting to $0.24.

  • Aurinia Pharmaceuticals' EPS (Basic) rose 14000.0% to $0.24 in Q3 2025 from the same period last year, while for Sep 2025 it was $0.58, marking a year-over-year increase of 48666.67%. This contributed to the annual value of $0.04 for FY2024, which is 10737.19% up from last year.
  • Latest data reveals that Aurinia Pharmaceuticals reported EPS (Basic) of $0.24 as of Q3 2025, which was up 14000.0% from $0.16 recorded in Q2 2025.
  • In the past 5 years, Aurinia Pharmaceuticals' EPS (Basic) registered a high of $0.24 during Q3 2025, and its lowest value of -$0.4 during Q1 2021.
  • Moreover, its 5-year median value for EPS (Basic) was -$0.09 (2023), whereas its average is -$0.11.
  • In the last 5 years, Aurinia Pharmaceuticals' EPS (Basic) plummeted by 7391.3% in 2021 and then soared by 150000.0% in 2025.
  • Over the past 5 years, Aurinia Pharmaceuticals' EPS (Basic) (Quarter) stood at -$0.26 in 2021, then grew by 28.75% to -$0.18 in 2022, then decreased by 2.39% to -$0.19 in 2023, then skyrocketed by 105.48% to $0.01 in 2024, then surged by 2230.87% to $0.24 in 2025.
  • Its EPS (Basic) stands at $0.24 for Q3 2025, versus $0.16 for Q2 2025 and $0.17 for Q1 2025.